|
市場調查報告書
生物科技的投資機會及商業趨勢
Pharma Antes Up: Investment and Business Trends Driving Biotechnology
|
本報告已在2011年12月21日停止出版。
受到研發效率低落、專利到期、規範壓力等因素影響，許多製藥企業都開始轉而進入生物科技產業。大型製藥企業企圖透過策略聯盟、夥伴關係、合併、收購等方式建立平台技術及更快地進入醫療實驗階段。
專門於醫療產業相關廣泛調查的美國市調公司Decision Resources Inc.(總公司：Massachusetts State) 針對生物科技的投資機會及商業趨勢進行調查分析，並出版經系統整理的報告書"Pharma Antes Up: Investment and Business Trends Driving Biotechnology" 。
本報告書內容包括：鉛化合物的開發、最適化、鑑定、標的鑑定及確定相關細節、企業購併動向、製藥企業及生物科技企業間的合作趨勢、2007年之後的市場發展預測等。內容綱要摘記如下：
實施概要
介紹
鉛化合物開發交易
鉛化合物最適化交易
鉛化合物鑑定交易
標的鑑定及確定交易
購併
- 製藥企業及生物科技企業
- 生物科技企業之間
- 逆向合併
未來發展預測：2007年之後
表
- 超過2億美元的製藥企業及生物科技企業的鉛化合物開發交易
- 超過1億美元的生物科技企業間の鉛化合物開發交易
- 鉛化合物最適化交易
- 鉛化合物鑑定交易
- 標的鑑定及標的確定交易
- 購併
圖
- 所有生物科學領域的購併
- 超過1億美元的製藥企業及生物科技企業、生物科技企業間的購併案數量
- 超過1億美元的製藥企業及生物科技企業、生物科技企業間的購併案金額
- 平台技術的價值循環
Abstract
Introduction:
Faced with weak pipelines, poor R&D productivity, expiring patents, and public
and regulatory pressure over safety, major pharmaceutical companies are
turning to the biotech industry for innovation. Much as in the late 1990s, Big
Pharma is enthusiastically pursuing platform technologies and early-stage
clinical candidates through a mix of strategic alliances, partnerships, and
mergers and acquisitions
Get the Answers You Need to Shape Your Strategy
- Big Pharma has expressed renewed interest in platform technologies and
early-stage clinical candidates originating from biotechnology companies.
What types of deals are occurring most frequently between these industries?
What approaches to drug discovery are of most interest to pharmaceutical
companies? What clinical trial phase is receiving the most attention from Big
Pharma?
- In addition to the growing interest from pharmaceutical companies, many
biotechs are also now participating in high-value partnerships with other
biotechs to fund drug development. How do biotech-biotech deals differ from
those involving Big Pharma? In what ways do biotech companies' long- and
short-term goals correspond to or differ from those of pharmaceutical
companies?
- Consolidation of the pharmaceutical and biotech industries has continued,
with a recent surge in the number of mergers and acquisitions. What
resources do pharmaceutical companies look for in companies when they consider
acquisitions? What platforms or indications have been highlighted as areas of
interest by Big Pharma? What does the emergence of reverse mergers say about
the state of the market?
- As the biotechnology industry continues to mature, biotech companies will
face more and more of the issues that typically plague Big Pharma. What are
the key issues that biotech companies will face as they mature? How will these
issues impact the risk and success of biotech drug development?
Scope
- Deal activity, by drug discovery stage: a review of deals for
compounds in lead development; lead optimization; lead identifi cation; and
target identifi cation and validation
- Mergers and acquisitions: a review of high-value ($100 million+)
M&A deals involving biotech, including a look at reverse mergers
- Deal participants: an examination of pharma-biotech and
biotech-biotech deal activity
- Market outlook: our forecast for trends in biotech dealmaking for
2007 and beyond
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- Lead Development Deals
- Pharma-Biotech
- Biotech-Biotech
- Lead Optimization Deals
- Lead Identifi cation Deals
- Pharma-Biotech
- Biotech-Biotech
- Target Identifi cation and Validation Deals
- Mergers and Acquisitions
- Pharma-Biotech
- Biotech-Biotech
- Reverse Mergers
- Outlook: 2007 and Beyond
Tables:
- 1. Select Pharma-Biotech Lead Development Deals with Values More Than $200
Million
- 2. Select Biotech-Biotech Lead Development Deals with Values More than
$100 Million
- 3. Select Lead Optimization Deals
- 4. Select Lead Identifi cation Deals
- 5. Select Target Identifi cation and Target Validation Deals
- 6. Select Mergers and Acquisitions
Figures:
- 1. All Life Science Mergers and Acquisitions
- 2. Number of Pharma-Biotech and Biotech-Biotech Mergers and Acquisitions
Valued at More Than $100 Million, 2002-2006
- 3. Total Value of Pharma-Biotech and Biotech-Biotech Mergers and
Acquisitions Valued at More Than $100 Million, 2002-2006
- 4. Cyclical Nature of the Value of Platform Technologies
|
